Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 52 of 2460 for:    Diabetes | "Diabetes Mellitus, Insulin-Dependent"

Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02218619
Recruitment Status : Active, not recruiting
First Posted : August 18, 2014
Last Update Posted : December 4, 2018
Sponsor:
Collaborator:
Juvenile Diabetes Research Foundation
Information provided by (Responsible Party):
Robin Goland, MD, Columbia University

Brief Summary:
Clinically, the ability to slow or prevent beta cell demise can prevent or improve the course of type 1 diabetes. The immune-mediated destruction of beta cells that is an apparent major pathological basis for the disease, has led to efforts to prevent or suppress this immune assault. Here we propose to buttress the beta cell's capacity to withstand this assault by improving the function of the endoplasmic reticulum stress resolving mechanisms within these cells. The ability to do so could have a major impact on preventive and therapeutic strategies for type 1 diabetes (and possibly other types of diabetes). The type of endoplasmic reticulum stress relieving agent (TUDCA) proposed here could ultimately be applied on an anticipatory basis to individuals at high risk for type 1 diabetes.

Condition or disease Intervention/treatment Phase
Type 1 Diabetes Drug: Tauroursodeoxycholic Acid (TUDCA) Drug: Sugar Pill (placebo) Phase 2

Detailed Description:

Reducing endoplasmic reticulum stress will promote beta cell survival in new-onset type 1 diabetes.

The primary aim is to test the clinical efficacy of an already approved agent, TUDCA, re-purposed to reduce endoplasmic reticulum stress and improve beta cell survival in patients with new onset type 1 diabetes. The primary endpoint of this proposed double-blinded randomized placebo-controlled pilot study is c-peptide measured after mixed meal stimulation test at randomization and then at 6 and 12 months of treatment with TUDCA compared to treatment with placebo and at 6 months following treatment.

TUDCA is an oral medication with an excellent safety profile that is approved for use in Europe for gall stones and liver disease. The drug and similar compounds has been used in children, as young as newborns, and in adults. TUDCA's ability to lower endoplasmic reticulum stress has only recently been recognized and will be applied to new-onset type 1 diabetes in this proposal. If this pilot trial is successful, future studies could include broadening the recipients to antibody-positive pre-type 1 diabetes patients and/or combining TUDCA with other agents shown to have a beneficial effect on insulin secretion in new-onset type 1 diabetes.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Clinical Investigation of Efficacy of Tauroursodeoxycholic Acid (TUDCA) to Enhance Pancreatic Beta Cell Survival In Type 1 Diabetes by Reducing Endoplasmic Reticulum Stress
Study Start Date : August 2015
Estimated Primary Completion Date : October 1, 2019
Estimated Study Completion Date : October 1, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: Taurourodeoxycholic Acid (TUDCA)
TUDCA 1750 mg/day x 12 months
Drug: Tauroursodeoxycholic Acid (TUDCA)
TUDCA at 1750 mg/day x 12 months
Other Names:
  • TUDCA
  • Taurolite

Placebo Comparator: Sugar pill (placebo)
Placebo at same dose, frequency, and duration as experimental treatment
Drug: Sugar Pill (placebo)
Placebo
Other Name: Placebo




Primary Outcome Measures :
  1. C-peptide measurement as reflection of insulin secretion [ Time Frame: 18 months ]
    The primary endpoint will be the area under the stimulated C-peptide curve over the first 2 hours of a 4- hour mixed meal tolerance test conducted at screening, and during the 12 months of drug treatment at 6 and12 months and at 6 months after drug or placebo is stopped.


Secondary Outcome Measures :
  1. Endoplasmic reticulum stress [ Time Frame: 1 week ]
    It is believed that the autoimmune assault of new onset type 1 diabetes leads to stress to the part of the beta cell that folds proteins; referred to as endoplasmic reticulum stress. When endoplasmic reticulum stress increases, changes in protein levels in beta cells occur. We will measure markers of endoplasmic reticulum stress in beta cells taken from skin biopsies taken from subjects before treatment with TUDCA or placebo.

  2. liver function tests [ Time Frame: 18 months ]
    We will measure liver function tests at 6 and 12 months and at 6 months after drug or placebo is stopped to ensure that no abnormalities of liver function occur with the drug.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 1 diabetes according to American Diabetes Association criteria
  • Diagnosis of type 1 diabetes within 100 days of randomization
  • One positive diabetes-related autoantibody
  • Ages 18-45 years

Exclusion Criteria:

  • Drugs known to affect glucose other than insulin
  • Stimulated C-peptide levels < 0.2 pmol/ml measured during a mixed meal tolerance test conducted at least 21 days from diagnosis of diabetes and within one month (37 days) of randomization to either TUDCA or placebo.
  • Women during pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02218619


Locations
Layout table for location information
United States, New York
Naomi Berrie Diabetes Center, Columbia University, 1150 St. Nicholas Ave.
New York, New York, United States, 10032
Sponsors and Collaborators
Robin Goland, MD
Juvenile Diabetes Research Foundation
Investigators
Layout table for investigator information
Principal Investigator: Robin Goland, MD Columbia University
Principal Investigator: Rudolph Leibel, MD Columbia University

Layout table for additonal information
Responsible Party: Robin Goland, MD, J. Merrill Eastman Professor of Clinical Diabetes, Co-Director, Berrie Center, Columbia University
ClinicalTrials.gov Identifier: NCT02218619     History of Changes
Other Study ID Numbers: AAAN2402
First Posted: August 18, 2014    Key Record Dates
Last Update Posted: December 4, 2018
Last Verified: December 2018
Keywords provided by Robin Goland, MD, Columbia University:
type 1 diabetes (T1D)
endoplasmic reticulum (ER) stress
induced pluripotential stem (iPS) cells
Tauroursodeoxycholic Acid (TUDCA)
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Tauroursodeoxycholic acid
Taurochenodeoxycholic Acid
Antiviral Agents
Anti-Infective Agents
Cholagogues and Choleretics
Gastrointestinal Agents